Back to top
more

Veracyte (VCYT)

(Delayed Data from NSDQ)

$31.83 USD

31.83
745,391

-0.45 (-1.39%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $31.83 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Henry Schein Stock to Gain From New Acquisitions Amid Macro Woes

by Zacks Equity Research

Henry Schein has strategically set up distribution centers worldwide to better serve customers and increase its operating efficiency.

Zacks Equity Research

Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?

by Zacks Equity Research

Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and WATCHMAN's performance.

Zacks Equity Research

Here's Why VCYT Stock Could be a Great Addition to Your Portfolio Now

by Zacks Equity Research

Veracyte's progress with key drivers and the strength in its diagnostics tests bring optimism to investors.

Zacks Equity Research

Here's Why You Should Add Ensign Group Stock to Your Portfolio Now

by Zacks Equity Research

ENSG should benefit from expanding facilities and growing footprint, leading to higher service revenues in the future.

Zacks Equity Research

The Zacks Analyst Blog Highlights Veracyte, Omnicell, Masimo and Abbott Laboratories

by Zacks Equity Research

Veracyte, Omnicell, Masimo and Abbott Laboratories are included in this Analyst Blog.

Zubia Masood headshot

Is Your Portfolio Missing These 5 High-Growth Healthcare Stocks?

by Zubia Masood

The Healthcare sector sees volume growth and improved occupancy while battling rising medical costs and regulatory uncertainty.

Urmimala Biswas headshot

4 Healthcare Technology Innovators to Invest in Before the New Year

by Urmimala Biswas

Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.

Zacks Equity Research

The Zacks Analyst Blog Highlights McKesson, Doximity and Veracyte

by Zacks Equity Research

McKesson, Doximity and Veracyte are included in this Analyst Blog.

Kaibalya Pravo Dey headshot

Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025

by Kaibalya Pravo Dey

The healthcare sector is undergoing significant changes, with technology, innovation and a patient-centric approach as the cornerstones of its growth.

Urmimala Biswas headshot

3 Medical Instruments Industry Stocks to Buy on the GenAI Wave

by Urmimala Biswas

MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects.

Zacks Equity Research

The Zacks Analyst Blog Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen

by Zacks Equity Research

Intuitive Surgical, Globus Medical, Glaukos, Veracyte and Inogen are included in this Analyst Blog.

Zacks Equity Research

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Zacks Equity Research

If You Invested $1000 in Veracyte a Decade Ago, This is How Much It'd Be Worth Now

by Zacks Equity Research

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Indrajit Bandyopadhyay headshot

5 Medical Device Stocks That Survived the 2024 Market Volatility

by Indrajit Bandyopadhyay

Here, we discuss five medical device stocks, namely ISRG, GMED, GKOS, VCYT and INGN, which gained in 2024 despite ongoing challenges and provide an attractive investment opportunity for 2025.

Zacks Equity Research

Veracyte Q3 Earnings Beat Estimates, 2024 Guidance Raised

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.

Zacks Equity Research

Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Veracyte (VCYT) delivered earnings and revenue surprises of 850% and 5.81%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HSIC Q3 Earnings Top, Margins Down, Stock Gains in Premarket

by Zacks Equity Research

Henry Schein's third-quarter results reflect an improvement in sales trends in Technology and Value-Added Services business.

Zacks Equity Research

ILMN Q3 Earnings Top, '24 Sales View Down, Stock Dips in Aftermarket

by Zacks Equity Research

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Zacks Equity Research

Hologic (HOLX) Q4 Earnings Miss Estimates

by Zacks Equity Research

Hologic (HOLX) delivered earnings and revenue surprises of -0.98% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

IDXX Q3 Earnings Top, '24 Sales View Down, Stock Dips in Premarket

by Zacks Equity Research

IDXX's Q3 revenues benefit from strong growth in its CAG and Water segments.

Zacks Equity Research

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

by Zacks Equity Research

Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.

Zacks Equity Research

CHE Misses on Q3 Earnings, Lowers '24 EPS View, Stock Up

by Zacks Equity Research

Chemed's VITAS segment reports impressive revenue growth and margin expansion for the third quarter of 2024.

Zacks Equity Research

Paragon 28, Inc. (FNA) Stock Jumps 7.2%: Will It Continue to Soar?

by Zacks Equity Research

Paragon 28, Inc. (FNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

ICLR Misses on Q3 Earnings, Lowers 2024 Guidance, Stock Falls

by Zacks Equity Research

ICON's third-quarter 2024 earnings lag estimates due to its large customers undergoing significant development model shifts with resulting cost pressures and the biotech market's slower recovery.

Zacks Equity Research

EW Q3 Earnings Match Estimates, Revenues Miss, Stock Falls

by Zacks Equity Research

Edwards Lifesciences reports strong contributions from all of the product groups - TAVR, TTMT and surgical structural heart - in the third quarter of 2024.